Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Private equity
Pharma
Bluebird investor reluctance pays off with better buyout offer
Bluebird bio investors are now offered an option to bag $5 per share in cash, an alternative to the original upfront-plus-CVR deal structure.
Angus Liu
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am
Bluebird bio receives rival M&A bid worth 50% higher
Mar 28, 2025 7:14pm
Once valued at $10B, struggling bluebird bio sold for $29M
Feb 21, 2025 10:56am
After M&A rumors, Bausch + Lomb confirms it's exploring a sale
Dec 12, 2024 11:26am
Supreme Group buys UK agency BioStrata, extending deal spree
Aug 21, 2024 8:00am
